SHC4 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q6S5L8 |
---|---|
Clone Names | 101008156 |
Gene ID | 399694 |
---|---|
Other Names | SHC-transforming protein 4, Rai-like protein, RaLP, SHC-transforming protein D, hShcD, Src homology 2 domain-containing-transforming protein C4, SH2 domain protein C4, SHC4, SHCD |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | SHC4 |
---|---|
Synonyms | SHCD |
Function | Activates both Ras-dependent and Ras-independent migratory pathways in melanomas. Contributes to the early phases of agrin-induced tyrosine phosphorylation of CHRNB1. |
Cellular Location | Postsynaptic cell membrane. Note=Colocalized with MUSK at the neuromuscular junction. |
Tissue Location | Only expressed in melanomas. Weakly expressed in normal melanocytes and benign nevi. Highly expressed at the transition from radial growth phase to vertical growth phase and metastatic melanomas, when tumor cells acquire migratory competence and invasive potential. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SHC4 activates both Ras-dependent and Ras-independent migratory pathways in melanomas. Contributes to the early phases of agrin-induced tyrosine phosphorylation of CHRNB1.
References
You, Y., et al. BMB Rep 43(7):485-490(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Jones, N., et al. Mol. Cell. Biol. 27(13):4759-4773(2007)Fagiani, E., et al. Cancer Res. 67(7):3064-3073(2007)Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.